Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed/ Refractory Acute Myeloid Leukemia (AMELI-01)
Not Recruiting
18-65 years
All
Phase
1
10 participants needed
1 Location
Brief description of study
This study is evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of UCART123v1.2 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D).
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Acute Myeloid Leukemia,Leukemia
-
Age: Between 18 Years - 65 Years
-
Gender: All
Male and Female, Age 18 - 65, Patients with relapsed or primary refractory Acute Myeloid Leukemia
Updated on
11 Sep 2024.
Study ID: 844364
